UC remission after anti-TNF failure more achievable with vedolizumab vs infliximab
23 Apr 2020
byJairia Dela Cruz
Ulcerative colitis (UC) patients with a primary nonresponse to an antitumour necrosis factor (anti-TNF) are more likely to achieve clinical remission with vedolizumab than with infliximab, as shown in a recent study.
UC remission after anti-TNF failure more achievable with vedolizumab vs infliximab
23 Apr 2020
